Objective:
To evaluate the efficacy and safety of sura vec, an anti-VEGF gene therapy, in treating nonproliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME).
Key Findings:
- 42% of control eyes experienced DRSS worsening compared to 17%, 0%, and 0% in the sura vec groups.
- Improvements of 2 or more steps in DRSS were seen in 8% of control eyes versus 33%, 21%, and 21% in the sura vec groups.
- At 2 years, 50% of patients in dose level 3 showed 2 or more step DRSS improvements.
- Vision-threatening event rates were significantly lower in sura vec groups (14%-33%) compared to historical controls (about 50%).
- Sura vec was well tolerated, with manageable side effects.
Interpretation:
Sura vec demonstrates potential as a durable and safer treatment option for NPDR, showing significant improvements in diabetic retinopathy severity and lower rates of vision-threatening events.
Limitations:
- Limited patient numbers in the study.
- Short follow-up duration for some cohorts.
Conclusion:
Sura vec shows promise as a well-tolerated and effective gene therapy for NPDR, warranting further investigation in pivotal trials.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.